Telix Pharmaceuticals Limited

TLX

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$11.33

−$1.09 · -8.78%

Aug 21, 3:55 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

46/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Fair Value

Momentum

Neutral

Sentiment

Mixed

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.

Industry: Biotechnology
Sector: Healthcare
Headquarters: AU
CEO: Christian Behrenbruch
Listed since: Nov 14, 2024
Employees: 1,152

Market position

Volume: 299.2K; 1.88× average
Average volume: 158.84K; Average daily volume
Market cap: 3.84B USD
Beta: 0.6; Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 4.28B AUD
P/E (TTM): 116.93×
P/B (TTM): 7.79×
P/S (TTM): 4.18×
EV / EBITDA: 53.59×
Earnings yield: -0.28%
Free cash flow yield: -2.18%
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 52.16%
Operating margin: -0.73%
Net margin: 3.60%
Return on equity: -1.72%
Return on assets: -0.60%
Return on invested capital: 1.83%

Financial health

Debt / equity: 1.19×
Current ratio: 1.43×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin

Income trends

Revenue

1.21B AUD+53.91%

Operating income

26.64M AUD-67.56%

Net income

−10.69M AUD−60.6M AUD

Metric (AUD)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1.21B AUD	783.21M AUD	502.55M AUD	160.1M AUD	7.6M AUD
Cost of goods sold	565.2M AUD	273.53M AUD	188.16M AUD	65.17M AUD	38.68M AUD
Gross profit	640.23M AUD	509.68M AUD	314.39M AUD	94.93M AUD	5.05M AUD
Research and development	256.82M AUD	121.03M AUD	128.84M AUD	57.86M AUD	34.14M AUD
Selling, general, and administrative	356.77M AUD	207.13M AUD	134.16M AUD	87.1M AUD	46.99M AUD
Operating expenses	613.59M AUD	427.55M AUD	263.27M AUD	186.86M AUD	53.3M AUD
Interest income	8.74M AUD	10.86M AUD	671K AUD	1K AUD	—
Interest expense	55.06M AUD	21.46M AUD	8.94M AUD	406K AUD	195.68K AUD
Depreciation and amortization	32.67M AUD	5.69M AUD	6.74M AUD	5.38M AUD	5.17M AUD
Operating income	26.64M AUD	82.13M AUD	15.84M AUD	−91.93M AUD	−81.25M AUD
Net income	−10.69M AUD	49.92M AUD	5.21M AUD	−104.08M AUD	−80.51M AUD